Press coverage about Dermira (NASDAQ:DERM) has trended positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Dermira earned a news impact score of 0.35 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Dermira, Inc. (NASDAQ:DERM) Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
- Suffering from excessive perspiration? Don't sweat it, we… (finance.yahoo.com)
- International Business Machines (NYSE:IBM) Experiences Lighter than Average Trading Volume (footballhebdo.com)
- NY Has $32.05 Million Position in Simon Property Group, Inc. (NYSE:SPG) (techzolix.com)
- UCB and Dermira Announce U.S. and EU Regulatory… (benzinga.com)
Shares of Dermira (NASDAQ DERM) traded down 1.69% on Friday, hitting $27.39. The company’s stock had a trading volume of 329,402 shares. The firm’s market cap is $1.14 billion. The company has a 50 day moving average of $29.20 and a 200 day moving average of $30.99. Dermira has a 1-year low of $25.63 and a 1-year high of $38.75.
A number of research analysts recently issued reports on the company. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Cantor Fitzgerald assumed coverage on Dermira in a research note on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $46.00 price target on shares of Dermira in a research note on Tuesday, July 18th. Evercore ISI assumed coverage on Dermira in a research note on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Mizuho dropped their price target on Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Dermira currently has a consensus rating of “Hold” and an average target price of $43.80.
ILLEGAL ACTIVITY WARNING: “Dermira (NASDAQ:DERM) Getting Positive Press Coverage, Study Finds” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/07/29/dermira-nasdaqderm-receiving-positive-media-coverage-report-finds-updated-updated-updated.html.
In other news, SVP Christopher M. Griffith sold 1,312 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $27.07, for a total transaction of $35,515.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eugene A. Bauer sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $30.01, for a total value of $75,025.00. The disclosure for this sale can be found here. Insiders have sold 16,312 shares of company stock valued at $468,441 over the last ninety days. Corporate insiders own 13.30% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.